Pfizer has two manufacturing facilities in Germany for high-potency manufacturing, respectively in Freiburg and Illertissen. Pharmaceutical Technology's Executive Editor Patricia Van Arnum visited the facilities and spoke to the company about the design and operation of these facilities.
Sep 1, 2012
By:
Patricia Van Arnum
Pfizer has two manufacturing facilities in Germany for high-potency manufacturing, respectively in Freiburg and Illertissen. Pharmaceutical Technology's Executive Editor Patricia Van Arnum visited the facilities and spoke to the company about the design and operation of these facilities.
|
Experts share insight on facility design and operations for high-potency manufacturing.
Sep 1, 2012
By:
Patricia Van Arnum
Experts share insight on facility design and operations for high-potency manufacturing.
|
A Q&A with BASF moderated by Patricia Van Arnum.
Sep 1, 2012
By:
Patricia Van Arnum
A Q&A with BASF moderated by Patricia Van Arnum.
|
|
An industry roundtable representing Metrics, Cambrex, Carbogen Amcis, Euticals, Ferro Pfanstiehl, and SAFC.
Sep 1, 2012
By:
Patricia Van Arnum
An industry roundtable representing Metrics, Cambrex, Carbogen Amcis, Euticals, Ferro Pfanstiehl, and SAFC.
|
Aug 22, 2012
By:
Patricia Van Arnum
Myriad Genetics reported that a US federal appeals court has ruled that the company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under federal patent law. The court, however, denied the company's effort to patent methods of "comparing" or "analyzing" DNA sequences.
|
Aug 22, 2012
By:
Patricia Van Arnum
Eli Lilly has received $1.3 billion for payment of financial obligations from Amylin Pharmaceuticals following Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals earlier this month.
|
An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.
Aug 7, 2012
By:
Patricia Van Arnum
An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.
|
|
Enhancing bioavailability can be achieved through hot-melt extrusion or spray drying. The drug product's API properties and stage of development are important factors to consider when deciding which technique to use.
Aug 2, 2012
By:
Patricia Van Arnum
Enhancing bioavailability can be achieved through hot-melt extrusion or spray drying. Patricia Van Arnum interviews Bend Research to find out more about when to use each technique.
|
|
Approaches center on ways to optimize process conditions and operability.
Aug 2, 2012
By:
Patricia Van Arnum
Approaches to scaling up API syntheses center on ways to optimize process conditions and operability.
|
|
